Shots:

• The P-III (QWINT-2 & QWINT-4) studies assess the safety & efficacy of efsitora (QW) vs insulin degludec (QD) for 52wks. to treat T2D patients using & not using GLP-1 receptor agonists and insulin glargine (QD) for 26wks. in T2D adults treated with basal insulin & at least two injections per day of mealtime insulin, respectively
• The QWINT-2 study showed 1.34% vs 1.26% reduction in A1C resulting in an A1C of 6.87% vs 6.95% (1EP). The 2EP showed efsitora's non-inferiority in A1C change among subjects using & not using GLP-1 receptor agonists. Additionally, subjects on efsitora spent 45mins. more time in range & 37mins. more in tight range without additional time in hypoglycemia
• The QWINT-4 study showed 1.07% reduction in A1C with both efsitora & insulin glargine resulting in an A1C of 7.12% vs 7.11% (1EP). In addition, the QWINT-2 study findings will be highlighted at EASD'24 while the topline results of QWINT-1, QWINT-3 & QWINT-5 are expected later in 2024

Ref: Eli Lilly | Image: Eli Lilly

Related News:- Eli Lilly Reports the P-III (SURMOUNT-OSA) Study Data of Tirzepatide in Patients with Obstructive Sleep Apnea (OSA) and Obesity

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com